CD274 and non-small cell lung carcinoma: For at least 25% of MICs and LICs, expanding access to the recommended fixed-dose PD1/PD-L1 inhibitor monotherapies for advanced NSCLC would result in significant expenditure, exceeding 1% to as much as 11% of the projected total pharmaceutical expenditure from 2024 to 2040 (Fig. 3a).